We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BEAM Stock Rallies More Than 25% in 3 Months: What Next?
Read MoreHide Full Article
Shares of Beam Therapeutics Inc. (BEAM - Free Report) have rallied 27.3% in the past three months compared with the industry’s increase of 9.8%.
Beam’s pipeline of gene editing therapies is based on its proprietary base editing technology. The company is advancing its base editing technology across three disease area portfolios, namely, hematology, immunology/oncology and genetic diseases.
The company is developing its leading ex-vivo genome-editing candidate, BEAM-101, for the treatment of sickle cell disease (SCD). The candidate is currently being evaluated in the phase I/II BEACON study for treating SCD. Initial data from the study is expected in 2024. Steady progress in the development of BEAM-101 could be a catalyst for the stock to increase during the abovementioned time period.
Also, the FDA recently approved two gene therapies for treating SCD. This has put the spotlight on companies that have promising gene editing candidates in their pipeline, including BEAM.
Image Source: Zacks Investment Research
We note that in October 2023, Beam announced a strategic restructuring to streamline its current portfolio of pipeline candidates and business operations. Following the portfolio prioritization, BEAM will mainly focus on the development of BEAM-101.
As part of the reprioritization, BEAM is looking to reduce its current headcount by 20%, which is likely to reduce costs.
Importantly, the restructuring and reprioritization efforts are expected to reduce the company’s operating expenses and extend the cash runway into 2026.
This apart, Beam is also developing in vivo base editor BEAM-302 for the treatment of alpha-1 antitrypsin deficiency. Regulatory applications to begin clinical studies on BEAM-302 in ex-U.S. markets are expected to be filed in the first quarter of 2024. The company will file an investigational new drug (IND) application with the FDA to begin clinical studies on BEAM-302 in the United States soon after.
The company is also planning to initiate a clinical study on BEAM-301 for the treatment of glycogen storage disease 1a in the United States. An IND application for BEAM-301 is expected to be filed in the first half of 2024.
Beam is evaluating BEAM-201 in a phase I/II study for treating patients with T-cell leukemia and T-cell lymphoblastic lymphoma and potentially other CD7+ malignancies.
Though still in the early stage, Beam’s pipeline holds great potential. If successfully developed and commercialized, BEAM-101 can significantly boost the company’s prospects and drive the stock in the days ahead.
However, competition in the target market remains a concern. A few other companies are also developing their own in-vivo and ex-vivo gene-editing therapies utilizing CRISPR/Cas9 nuclease technology.
In the past 60 days, estimates for Dynavax Technologies’ 2024 earnings per share have improved from 8 cents to 18 cents. In the past year, shares of DVAX have surged 36%.
Earnings of Dynavax Technologies beat estimates in two of the last four quarters while missing the same on the remaining two occasions. DVAX delivered a four-quarter earnings surprise of 293.21%, on average.
In the past 60 days, estimates for Entrada Therapeutics’ 2024 loss per share have narrowed from $2.35 to $2.04. In the past year, shares of TRDA have gained 23%.
Earnings of Entrada Therapeutics beat estimates in three of the last four quarters while missing the same on the remaining one occasion. TRDA delivered a four-quarter average earnings surprise of 70.68%.
In the past 60 days, estimates for Puma Biotechnology’s 2024 earnings per share have improved from 56 cents to 69 cents. In the past year, shares of PBYI have gained 7.7%.
Earnings of Puma Biotechnology beat estimates in three of the last four quarters while missing the same on the remaining one occasion. PBYI delivered a four-quarter average earnings surprise of 76.55%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
BEAM Stock Rallies More Than 25% in 3 Months: What Next?
Shares of Beam Therapeutics Inc. (BEAM - Free Report) have rallied 27.3% in the past three months compared with the industry’s increase of 9.8%.
Beam’s pipeline of gene editing therapies is based on its proprietary base editing technology. The company is advancing its base editing technology across three disease area portfolios, namely, hematology, immunology/oncology and genetic diseases.
The company is developing its leading ex-vivo genome-editing candidate, BEAM-101, for the treatment of sickle cell disease (SCD). The candidate is currently being evaluated in the phase I/II BEACON study for treating SCD. Initial data from the study is expected in 2024. Steady progress in the development of BEAM-101 could be a catalyst for the stock to increase during the abovementioned time period.
Also, the FDA recently approved two gene therapies for treating SCD. This has put the spotlight on companies that have promising gene editing candidates in their pipeline, including BEAM.
We note that in October 2023, Beam announced a strategic restructuring to streamline its current portfolio of pipeline candidates and business operations. Following the portfolio prioritization, BEAM will mainly focus on the development of BEAM-101.
As part of the reprioritization, BEAM is looking to reduce its current headcount by 20%, which is likely to reduce costs.
Importantly, the restructuring and reprioritization efforts are expected to reduce the company’s operating expenses and extend the cash runway into 2026.
This apart, Beam is also developing in vivo base editor BEAM-302 for the treatment of alpha-1 antitrypsin deficiency. Regulatory applications to begin clinical studies on BEAM-302 in ex-U.S. markets are expected to be filed in the first quarter of 2024. The company will file an investigational new drug (IND) application with the FDA to begin clinical studies on BEAM-302 in the United States soon after.
The company is also planning to initiate a clinical study on BEAM-301 for the treatment of glycogen storage disease 1a in the United States. An IND application for BEAM-301 is expected to be filed in the first half of 2024.
Beam is evaluating BEAM-201 in a phase I/II study for treating patients with T-cell leukemia and T-cell lymphoblastic lymphoma and potentially other CD7+ malignancies.
Though still in the early stage, Beam’s pipeline holds great potential. If successfully developed and commercialized, BEAM-101 can significantly boost the company’s prospects and drive the stock in the days ahead.
However, competition in the target market remains a concern. A few other companies are also developing their own in-vivo and ex-vivo gene-editing therapies utilizing CRISPR/Cas9 nuclease technology.
Beam Therapeutics Inc. Price
Beam Therapeutics Inc. price | Beam Therapeutics Inc. Quote
Zacks Rank & Stocks to Consider
Beam currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the healthcare sector are Dynavax Technologies Corporation (DVAX - Free Report) , Entrada Therapeutics, Inc. (TRDA - Free Report) and Puma Biotechnology, Inc. (PBYI - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Dynavax Technologies’ 2024 earnings per share have improved from 8 cents to 18 cents. In the past year, shares of DVAX have surged 36%.
Earnings of Dynavax Technologies beat estimates in two of the last four quarters while missing the same on the remaining two occasions. DVAX delivered a four-quarter earnings surprise of 293.21%, on average.
In the past 60 days, estimates for Entrada Therapeutics’ 2024 loss per share have narrowed from $2.35 to $2.04. In the past year, shares of TRDA have gained 23%.
Earnings of Entrada Therapeutics beat estimates in three of the last four quarters while missing the same on the remaining one occasion. TRDA delivered a four-quarter average earnings surprise of 70.68%.
In the past 60 days, estimates for Puma Biotechnology’s 2024 earnings per share have improved from 56 cents to 69 cents. In the past year, shares of PBYI have gained 7.7%.
Earnings of Puma Biotechnology beat estimates in three of the last four quarters while missing the same on the remaining one occasion. PBYI delivered a four-quarter average earnings surprise of 76.55%.